CA2420177C - Quinazoline derivatives as alpha-1 adrenergic antagonists - Google Patents
Quinazoline derivatives as alpha-1 adrenergic antagonists Download PDFInfo
- Publication number
- CA2420177C CA2420177C CA002420177A CA2420177A CA2420177C CA 2420177 C CA2420177 C CA 2420177C CA 002420177 A CA002420177 A CA 002420177A CA 2420177 A CA2420177 A CA 2420177A CA 2420177 C CA2420177 C CA 2420177C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- amino
- compound
- phenyl
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22950300P | 2000-08-31 | 2000-08-31 | |
| US60/229,503 | 2000-08-31 | ||
| PCT/EP2001/009749 WO2002018348A2 (en) | 2000-08-31 | 2001-08-23 | Quinazoline derivatives as alpha-1 adrenergic antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2420177A1 CA2420177A1 (en) | 2002-03-07 |
| CA2420177C true CA2420177C (en) | 2008-07-08 |
Family
ID=22861517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002420177A Expired - Fee Related CA2420177C (en) | 2000-08-31 | 2001-08-23 | Quinazoline derivatives as alpha-1 adrenergic antagonists |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6559153B2 (https=) |
| EP (1) | EP1315714B1 (https=) |
| JP (1) | JP3971299B2 (https=) |
| KR (1) | KR100602929B1 (https=) |
| CN (1) | CN1308324C (https=) |
| AR (1) | AR032475A1 (https=) |
| AT (1) | ATE309240T1 (https=) |
| AU (2) | AU2001293788B2 (https=) |
| BR (1) | BR0113585A (https=) |
| CA (1) | CA2420177C (https=) |
| DE (1) | DE60114852T2 (https=) |
| ES (1) | ES2251512T3 (https=) |
| GT (1) | GT200100181A (https=) |
| MX (1) | MXPA03001777A (https=) |
| PA (1) | PA8527901A1 (https=) |
| PE (1) | PE20020407A1 (https=) |
| UY (1) | UY26919A1 (https=) |
| WO (1) | WO2002018348A2 (https=) |
| ZA (1) | ZA200301082B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500373A (ja) | 2001-08-10 | 2005-01-06 | ポリチップ ファーマスーティカルズ プロプライエタリイ リミテッド | モルヒネ様オピオイド化合物の誘導体 |
| CA2480266C (en) * | 2002-04-03 | 2011-07-12 | Orion Corporation | Use of an alpha2-adrenoreceptor antagonist for cns-related diseases |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
| DE602004022819D1 (de) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| AU2004259357B2 (en) | 2003-07-24 | 2010-02-18 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| WO2006021345A2 (en) * | 2004-08-27 | 2006-03-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b) |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7344583B2 (en) * | 2005-03-31 | 2008-03-18 | 3M Innovative Properties Company | Methods of making metal particles within cored dendrimers |
| US7413607B2 (en) * | 2005-03-31 | 2008-08-19 | 3M Innovative Properties Company | Templated semiconductor particles and methods of making |
| ATE449082T1 (de) | 2005-05-04 | 2009-12-15 | Hoffmann La Roche | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| JP5144666B2 (ja) * | 2006-09-19 | 2013-02-13 | スリーエム イノベイティブ プロパティズ カンパニー | 鋳型化された金属酸化物粒子及び製造方法 |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| TW200944526A (en) * | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| EP2694056B1 (en) | 2011-04-01 | 2019-10-16 | AstraZeneca AB | Therapeutic treatment |
| PH12014500943A1 (en) | 2011-11-30 | 2014-06-30 | Astrazeneca Ab | Combination treatment of cancer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| AU2018236130A1 (en) * | 2017-03-12 | 2019-09-19 | Xiaodong Wang | Polycyclic amines as opioid receptor modulators |
| WO2019088095A1 (ja) * | 2017-11-02 | 2019-05-09 | 国立大学法人九州大学 | 鎮痛剤及びその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11512710A (ja) | 1995-09-29 | 1999-11-02 | メルク エンド カンパニー インコーポレーテッド | アルファ1bアドレナリンレセプターアンタゴニスト |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| US6355641B1 (en) | 1999-03-17 | 2002-03-12 | Syntex (U.S.A.) Llc | Oxazolone derivatives and uses thereof |
-
2001
- 2001-08-23 BR BR0113585-6A patent/BR0113585A/pt not_active IP Right Cessation
- 2001-08-23 AU AU2001293788A patent/AU2001293788B2/en not_active Ceased
- 2001-08-23 JP JP2002523466A patent/JP3971299B2/ja not_active Expired - Fee Related
- 2001-08-23 WO PCT/EP2001/009749 patent/WO2002018348A2/en not_active Ceased
- 2001-08-23 CA CA002420177A patent/CA2420177C/en not_active Expired - Fee Related
- 2001-08-23 KR KR1020037002933A patent/KR100602929B1/ko not_active Expired - Fee Related
- 2001-08-23 CN CNB018165958A patent/CN1308324C/zh not_active Expired - Fee Related
- 2001-08-23 AT AT01974210T patent/ATE309240T1/de not_active IP Right Cessation
- 2001-08-23 ES ES01974210T patent/ES2251512T3/es not_active Expired - Lifetime
- 2001-08-23 MX MXPA03001777A patent/MXPA03001777A/es active IP Right Grant
- 2001-08-23 EP EP01974210A patent/EP1315714B1/en not_active Expired - Lifetime
- 2001-08-23 AU AU9378801A patent/AU9378801A/xx active Pending
- 2001-08-23 DE DE60114852T patent/DE60114852T2/de not_active Expired - Fee Related
- 2001-08-29 PE PE2001000870A patent/PE20020407A1/es not_active Application Discontinuation
- 2001-08-29 US US09/942,385 patent/US6559153B2/en not_active Expired - Fee Related
- 2001-08-30 GT GT200100181A patent/GT200100181A/es unknown
- 2001-08-30 AR ARP010104130A patent/AR032475A1/es unknown
- 2001-08-30 UY UY26919A patent/UY26919A1/es not_active Application Discontinuation
- 2001-08-30 PA PA20018527901A patent/PA8527901A1/es unknown
-
2003
- 2003-02-07 ZA ZA200301082A patent/ZA200301082B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20020407A1 (es) | 2002-05-21 |
| EP1315714A2 (en) | 2003-06-04 |
| AR032475A1 (es) | 2003-11-12 |
| JP3971299B2 (ja) | 2007-09-05 |
| JP2004507527A (ja) | 2004-03-11 |
| PA8527901A1 (es) | 2002-07-30 |
| KR20030022421A (ko) | 2003-03-15 |
| CN1545510A (zh) | 2004-11-10 |
| UY26919A1 (es) | 2002-02-28 |
| KR100602929B1 (ko) | 2006-07-20 |
| US6559153B2 (en) | 2003-05-06 |
| AU2001293788B2 (en) | 2007-10-11 |
| AU9378801A (en) | 2002-03-13 |
| ATE309240T1 (de) | 2005-11-15 |
| DE60114852D1 (de) | 2005-12-15 |
| DE60114852T2 (de) | 2006-07-27 |
| CN1308324C (zh) | 2007-04-04 |
| MXPA03001777A (es) | 2003-06-04 |
| WO2002018348A3 (en) | 2002-07-11 |
| GT200100181A (es) | 2002-05-23 |
| CA2420177A1 (en) | 2002-03-07 |
| ZA200301082B (en) | 2004-05-07 |
| EP1315714B1 (en) | 2005-11-09 |
| US20020045614A1 (en) | 2002-04-18 |
| ES2251512T3 (es) | 2006-05-01 |
| BR0113585A (pt) | 2003-07-29 |
| WO2002018348A2 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2420177C (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
| AU2001293788A1 (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
| EP1363899B1 (en) | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists | |
| AU2001260310B2 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| US6319920B1 (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives | |
| US6864266B2 (en) | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | |
| WO2000055143A1 (en) | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators | |
| EP1453806B1 (en) | Aminotetralin derivatives as muscarinic receptor antagonist | |
| JP2009513502A (ja) | アリールアミン置換キナゾリノン化合物 | |
| JP2009513504A (ja) | 5−置換キナゾリノン誘導体 | |
| US6355641B1 (en) | Oxazolone derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |